REG - Hemogenyx Pharma Plc - CBR Intranasal Delivery

Hemogenyx PharmaceuticalsAnnouncement

14/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240214:nRSN0399Da&default-theme=true

RNS Number : 0399D  Hemogenyx Pharmaceuticals PLC  14 February 2024

14 February 2024

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

 

CBR Intranasal Delivery

 

Chimeric Bait Receptors for Combatting Airborne Viral Infections Can Be
Delivered Intranasally

 

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical stage
biopharmaceutical group, announces that it has demonstrated in vivo that its
proprietary Chimeric Bait Receptor ("CBR") can be delivered intranasally in
the form of messenger RNA ("mRNA") for the potential treatment of airborne
viral infections.

CBR-based countermeasures against viral infections that are  include a novel
method of their delivery. To satisfy real-world requirements for the
deployment of such countermeasures, they must be both easy to administer and
have a long shelf life at ambient temperatures. CBR is a platform technology
under development that aims to program the immune cells that are responsible
for innate immunity (e.g., macrophages) to eliminate viruses and certain
malignant cells.

Our team of scientists has demonstrated in vivo that mRNA encoding a CBR-based
therapeutic can be mixed with a polymer and a solvent at room temperature to
form polymer nanoparticles encapsulating mRNA. Such nanoparticles can be used
to deliver CBR-coding mRNA into the upper respiratory tract ("URT") and lungs
of small animals. Once administered, nanoparticles were shown to successfully
deliver mRNA into the immune cells of the URT and lungs. The immune cells in
turn begin making CBR molecules within hours post-application, potentially
becoming active "defenders" against airborne infections.

As previously reported, the Company has been able to dramatically accelerate
its research and development efforts by using Artificial Intelligence ("AI")
and in-house synthesis of mRNA. AI tools allow the Company's scientists to
triage variants of CBR constructs efficiently to select those with the
greatest likelihood of success, while in-house mRNA synthesis facilitates the
rapid building of CBR constructs.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented: "This major breakthrough in the method of delivery of our CBR
demonstrates that it could potentially be used as an off-the-shelf prevention
and/or treatment for viral infections. Intranasal delivery of CBR would be
both cost-efficient and easy to administer, making it ideal for the protection
of both the civilian population and in biodefense."

 

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been inside
information for the purposes of Article 7 of Regulation No 596/2014 (as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement.

 

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)

 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl

 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

The Company is a clinical-stage biopharmaceutical group developing new
medicines and treatments for life-threatening diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as a platform technology that it uses as an engine for
novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFAFUDELSEDE